The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study.
Older age, longer diabetes duration, higher HbA1c tied to increased risk for pacemaker transplantation.
Odds of elevated blood pressure and stage 1, 2 hypertension increased with moderate drinking.
In adults with diabetes, high CAC score predicts CVD, total mortality more strongly in women than in men.
Relationship modified by overall sleep patterns, especially with daytime sleepiness.
The long-acting human insulin analogue has an identical amino acid sequence to Lantus® (insulin glargine; Sanofi).
The 2020 ADA guideline update reflects evidence from recent major trials with cardiovascular and renal outcomes.
Researchers investigated the association between gout, urate-lowering therapy use, and the risk of developing type 2 diabetes.
Dapagliflozin appears to preserve kidney function and improve survival in patients with chronic kidney disease whether or not they have type 2 diabetes.
The FDA concluded “the risk no longer meets the standard for a Boxed Warning.”